BioSight
Companies
Trevi Therapeutics, Inc. logo

TRVI

NASDAQNEW HAVEN, CT
Trevi Therapeutics, Inc.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release formulation of nalbuphine, to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Haduvio works by acting on opioid receptors in the cough reflex arc as a kappa receptor agonist and mu receptor antagonist, with nalbuphine having a decades-long safety record as an injectable pain medication. The lead program for IPF-related chronic cough recently completed a Phase 2b dose-ranging trial with positive results announced in June 2025.

Price history not yet available for TRVI.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar